Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20774001 | 0.91 | KDM4E (0.44) | KDM4EALDH1A1POLA1MEN1KMT2A | |
| SCHEMBL23326502 | 0.90 | HPGD (0.39) | MEN1KMT2A | |
| SCHEMBL23326713 | 0.88 | KDM4E (0.41) | KDM4EALDH1A1POLA1TAS1R3TAS1R1 | |
| SCHEMBL25741210 | 0.80 | CYP3A4 (0.31) | — | |
| SCHEMBL25741209 | 0.80 | CYP3A4 (0.31) | — | |
| SCHEMBL20250994 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1POLA1MEN1KMT2A | |
| SCHEMBL23351465 | 0.78 | KDM4E (0.45) | KDM4EALDH1A1POLA1MEN1KMT2A | |
| SCHEMBL23326496 | 0.75 | ADORA2B (0.32) | — | |
| SCHEMBL20773596 | 0.74 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2ATAS1R3 | |
| SCHEMBL25496217 | 0.71 | KDM4E (0.47) | KDM4EALDH1A1MEN1KMT2ATAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267844-B2 | Spirothietane nucleosides | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-08 | — | — | US | disclosed |
| EP-3676276-B1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-08 | — | — | EP | disclosed |
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267844-B2 | Spirothietane nucleosides | SAMHD1, SLC28A1, SLC28A2 | KDM4E 2709/4885ALDH1A1 521/4885POLA1 1326/4885 |
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | SAMHD1, SLC28A1, SLC28A2 | KDM4E 2709/4885ALDH1A1 521/4885POLA1 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.